BiotechTube

Dupilumab

Phase 2UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Atopic Keratoconjunctivitis

Conditions

Atopic Keratoconjunctivitis

Trial Timeline

Feb 10, 2020 → Jan 1, 2025

NCT ID
NCT04296864

About Dupilumab

Dupilumab is a phase 2 stage product being developed by Regeneron Pharmaceuticals for Atopic Keratoconjunctivitis. The current trial status is unknown. This product is registered under clinical trial identifier NCT04296864. Target conditions include Atopic Keratoconjunctivitis.

What happened to similar drugs?

20 of 20 similar drugs in Atopic Keratoconjunctivitis were approved

Approved (20) Terminated (1) Active (0)
✅LebrikizumabEli LillyApproved
✅tacrolimus 0.1% + fluticasone 0.005 %Astellas PharmaApproved
✅tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
✅tacrolimusAstellas PharmaApproved
✅tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
✅Tacrolimus 0.03% + Fluticasone 0.005%Astellas PharmaApproved
✅Protopic + Corticosteroid + placeboAstellas PharmaApproved

Hype Score Breakdown

Clinical
12
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (16)

NCT IDPhaseStatus
NCT06631677Pre-clinicalCompleted
NCT04776694Pre-clinicalCompleted
NCT06226610Phase 2Recruiting
NCT05042258ApprovedRecruiting
NCT06012448ApprovedCompleted
NCT05720325Phase 2Recruiting
NCT05268107ApprovedRecruiting
NCT05128383Phase 2Completed
NCT05265234ApprovedUNKNOWN
NCT05036733ApprovedCompleted
NCT05246267Pre-clinicalRecruiting
NCT04148352Phase 2Terminated
NCT04296864Phase 2UNKNOWN
NCT03935971ApprovedActive
NCT03886493Phase 2Terminated
NCT03667014ApprovedCompleted

Competing Products

20 competing products in Atopic Keratoconjunctivitis

See all competitors
ProductCompanyStageHype Score
LebrikizumabEli LillyPhase 3
40
Baricitinib + Placebo + Topical corticosteroidEli LillyPhase 3
40
LebrikizumabEli LillyApproved
50
LebrikizumabEli LillyPhase 3
40
Lebrikizumab + PlaceboEli LillyPhase 3
44
BioLexa- Cohort 1 + BioLexa- Cohort 2 + Placebo + GentamicinHoth TherapeuticsPhase 1
19
LebrikizumabEli LillyPhase 3
40
ASN008Formation BioPhase 2
25
ENS-002Concerto BiosciencesPhase 1
11
nemolizumab (CIM331)Chugai PharmaceuticalPhase 2
35
YH35324 + Placebo + OmalizumabYuhanPhase 1
29
YH35324 + Placebo + OmalizumabYuhanPhase 1
29
DS-2741a + PlaceboDaiichi SankyoPhase 1
21
SUN13834 + PlaceboDaiichi SankyoPhase 2
35
5 mg ASB17061 + Placebo + 10 mg ASB17061 + 20 mg ASB17061Daiichi SankyoPhase 2
35
Tacrolimus Ointment 0.03% + Tacrolimus Ointment 0.03%Astellas PharmaPhase 2
35
tacrolimus ointmentAstellas PharmaPhase 3
40
tacrolimus 0.1% + fluticasone 0.005 %Astellas PharmaApproved
43
tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
43
tacrolimus ointment 0.03% + hydrocortisone acetate ointment 1% + hydrocortisone butyrate ointment 0.1% + Meningitec + AC VAXAstellas PharmaPhase 2
35